top of page

HekaBio’s 1st Issuance of New Shares(English translation)

HekaBio’s 1st Issuance of New Shares

On March 20, 2018, HekaBio K.K., a Tokyo based bio-venture start-up will issue a third-party allotment of new shares.

With the mission of contributing to Japanese society’s medical and healthcare markets, HekaBio K.K. was established to specialize in the development and commercialization of innovative therapies originating from overseas.

Targeting cancer and autoimmune/inflammatory disorders, HekaBio endeavors to close the gap in access to life changing therapies for patients suffering from diseases without current solutions.

HekaBio’s veteran team leverages its experience and know-how developed at two related firms—Junicon K.K., a global medical market research-based consultancy established in Tokyo in 1992, and Vorpal Technologies K.K., a pharmaceutical and medical device CRO established in Tokyo in 2013.

Through this issue of new shares, HekaBio K.K. will continue its portfolio expansion and product development based on the company mission to address the unmet needs of patients and medical professionals in Japan.

About HekaBio K.K.

Registered: November 8, 2017

Office: Yashima Bldg. 3F, 2-7-14 Toranomon, Minato-ku, Tokyo 105-0001

Tel: +81 (3) 6205-7585 Fax: +81 (3) 6205-7586

Paid-in Capital: 180 million JPY

Chief Executive Officer: Robert E. Claar

HekaBio focuses on cancer, autoimmune/ inflammatory and central nervous system disease. The management team has extensive experience and networks, both overseas and in Japan.

With a deep understanding and respect for Japanese medical needs and business practices, HekaBio continues to grow by developing its innovation pipeline with validated programs from overseas partners. HekaBio strives to eliminate the innovation gap between Japan and rest of the world with the swift launch of therapies meeting unmet medical needs in Japan.

With integrity and tenacity, HekaBio collaborates with healthcare and business partners to creatively address the unmet medical needs of patients who are fighting rare and intractable diseases.



bottom of page